Intriguingly, PFS was found to be longer in ANA-positive patients treated by PD-1/PD-L1 inhibitors across tumor types (13.1 versus 7.0 months, p = 0.015), even when the confounding factors (including TNM stage and cancer type) were adjusted. The gene discussed is BTG3; the disease is cancer.